Company Profile

Adolor Corporation
Profile last edited on: 10/12/22            CAGE: 59F96

Analgesic pharmaceuticals: pain management
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

700 Pennsylvania Avenue
Exton, PA 19341
   (484) 595-1500
Location: Multiple
Congr. District: 06
County: Chester

Public Profile

In December 2011, Adolor was acquired by Cubist in an all cash deal. Cubist was itself an SBIR awardee that subsequently engaged with several other younger firms in the program. Adolor Corporation is a development stage biopharmaceutical corporation that discovers, develops and plans to commercialize proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by pain treatments. The Company's lead product candidate, alvimopan, is designed to selectively block the unwanted effects of opioid analgesics on the gastrointestinal tract. The Company's other product candidates are being designed as analgesics to treat moderate-to-severe pain and itch. Additionally, the Company is exploring the development of an analgesic product candidate that would be a combination of alvimopan and an opioid that would be intended to produce the pain relief of an opioid while reducing side effects, such as constipation, nausea and vomiting. In keeping with the movement toward improved pain management (including the increased use of opioids like hydrocodone), the company is developing drugs that alleviate the side effects of some pain treatments. Adolor's lead drug candidate Entereg may reduce opioid-induced side effects such as bowel dysfunction. The company has partnered with GlaxoSmithKline for development and of Entereg as a treatment for opioid-related side effects and for postoperative ileus (or intestinal obstruction). The two companies halted development of Entereg for opioid-induced bowel dysfunction in 2007.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2001 1 NIH $106,026
Project Title: Discovery of K Opioid Analgesics Using Chimeric Receptor
2001 2 NIH $922,141
Project Title: Identification of Novel Ligands for the ORL-1 Receptor
2001 1 NIH $157,110
Project Title: Novel Cannabinoid Receptor Agonists as Analgesics

Key People / Management

  Michael R Dougherty -- President

  Diane L Dehaven

  Patrick Little

  Bruce A Peacock -- former President

  Peter J Schied -- Chief Financial Officer